HC Wainwright & Co. Maintains Buy on Cara Therapeutics, Lowers Price Target to $2.5
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Oren Livnat has maintained a Buy rating on Cara Therapeutics (NASDAQ:CARA) but has reduced the price target from $7 to $2.5.

December 19, 2023 | 11:22 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Cara Therapeutics' price target has been lowered from $7 to $2.5 by HC Wainwright & Co., although the Buy rating is maintained.
The reduction in price target by a significant margin from $7 to $2.5, while maintaining a Buy rating, suggests that the analyst sees potential in the company but acknowledges near-term challenges or valuation adjustments that could pressure the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100